New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma Abstract | Childhood-onset craniopharyngiomas are rare embryonic tumours of low-grade histological malignancy. Novel insights into the molecular pathogenesis of human adamantinomatous craniopharyngioma have started to unveil the possibility of testing novel treatments targeting pathogenic pathways. Hypothalamic involvement and/or treatment-related lesions result in impaired physical and social functionality and in severe neuroendocrine sequelae. Quality of survival in patients with craniopharyngioma with hypothalamic involvement is impaired by severe obesity, physical fatigue and non-optimal psychosocial development. Patients with craniopharyngioma involving hypothalamic structures have reduced 20-year overall survival, but overall and progression-free survival are not related to the degree of surgical resection. Irradiation is effective in the prevention of tumour progression and recurrence. For favourably localized craniopharyngiomas, the preferred treatment of choice is to attempt complete resection with preservation of visual, hypothalamic and pituitary function. For unfavourably localized tumours in close proximity to optic and/or hypothalamic structures, a radical neurosurgical strategy attempting complete resection is not recommended owing to potential severe sequelae. As expertise has been shown to have an impact on post-treatment morbidity, medical societies should establish criteria for adequate professional expertise for the treatment of craniopharyngioma. On the basis of these criteria, health authorities should organize the certification of centres of excellence that are authorized to treat and care for patients with this chronic disease.
affects secretion of growth hormone (in 75% of patients), gonadotropins (in 40% of patients), TSH (in 25% of patients) and adrenocorticotropic hormone (in 25% of patients) 9 . In one study, the median duration of history was 6 months (range: 0.1-108 months) and correlated positively with age at diagnosis 10 . Tumour size, hypothalamic involvement, degree of resection and BMI at diagnosis were not related to duration of history 10 . In multi variate analysis adjusted for age at diagnosis, only hydrocephalus was found to have a significant influence on the duration of history. Visual and neurological deficits were associated with larger initial tumour size and impaired 10-year overall survival. Weight gain and growth failure were observed with the longest duration of history. Progression-free survival and functional capacity were not related to any specific symptom. Endocrine deficits at diagnosis were associated with a long duration of history 10 . Important anatomical hallmarks that help to achieve a precise preoperative MRI diagnosis of the accurate topographical relationships between the tumour and the hypothalamus-optic chiasm-third ventricle have been reported 11, 12 . The solid mammillary bodies are grossly displaced and/or distorted by lesions involving the hypothalamus but do not, as a rule, become invaded by the tumour. Preoperative identification of the position and distortion of the mammillary bodies can help to predict the relative position and adherence of the distorted hypothalamus 13 . The use of heavily T2-weighted MRI 14 and fast imaging employing steady-state acquisition (FIESTA) MRI sequences 15 enable optimal identification of the brain-craniopharyngioma interface and the relative position of the hypothalamus, both of which are essential for the planning of surgical and/or radiotherapy treatments.
Molecular pathology
The vast majority of, probably all, human adamantinomatous craniopharyngioma tumours are recognized to harbour overactivating mutations in the gene encoding β-catenin (CTNNB1) [16] [17] [18] [19] . Of note, the papillary form of craniopharyngioma, which usually presents in elderly individuals, harbours BRAF p.V600E mutations and shows distinct methylation profiles, which indicates that adamantinomatous craniopharyngioma and papillary craniopharyngioma are different molecular entities 19, 20 . In 2015, the coexistence of BRAF p.V600E and CTNNB1 mutations was reported in one case of adamantinomatous craniopharyngioma 21 . Additional molecular analyses are required to identify which, if any, other recurrent mutations are present in human adamantinomatous craniopharyngiomas in addition to those in CTNNB1. Nonetheless, human adamantinomatous craniopharyngioma seems to be a tumour with a low mutation burden.
Most of the identified mutations in adamantinomatous craniopharyngioma lie in regulatory amino acids encoded by exon 3 of CTNNB1 (REF. 22 ). The molecular consequence of such mutations is the expression of a mutant form of β-catenin with increased resistance to degradation, which results in the accumulation of β-catenin and subsequent activation of the WNT pathway. This accretion is supported by reports that human adamantinomatous craniopharyngiomas contain cells with nucleocytoplasmic accumulation of β-catenin, which are either dispersed throughout the tumours or grouped in whorls of cells that are termed 'cell clusters' (REF. [23] [24] [25] . These clusters are not present in any other pituitary tumour and represent a histological hallmark of human adamantinomatous craniopharyngioma 26 . Tumour cells, including cell clusters, activate the WNT pathway, as evidenced by the expression of WNT target genes such as AXIN2 or lymphoid enhancer-binding factor 1 (LEF1) 23, 24 . Gene expression profiling studies of human adamantinomatous craniopharyngioma have been performed to characterize the pathogenetic events downstream of activation of the WNT-β-catenin signalling pathway 20, 27 . These studies have revealed several pathways that are deregulated in these tumours as a consequence of overactivation of the WNT-β-catenin pathway (FIG. 1) . Many of the deregulated pathways are targetable with specific inhibitors, which could potentially provide new therapeutic opportunities for treating patients with craniopharyngiomas. The next logical step is to perform well-designed preclinical studies to determine the function of these pathways in the biology of these tumours. These preclinical studies will inform whether a particular pathway has antitumorigenic or pro-tumorigenic effects
Key points
• The clinical, neuroradiological and surgical definition of hypothalamic involvement is a fundamental factor related to poor postoperative outcome, progressive obesity and neuropsychological impairment in children after surgical removal of craniopharyngioma • The previously assumed 'gold-standard' objective of a primary radical removal of the lesion in all cases needs to be replaced with the new paradigm of a limited resection plus focused radiotherapy in patients with craniopharyngioma and hypothalamic lesions • Hypothalamic involvement and treatment-related hypothalamic lesions are associated with the highest risk of postoperative sequelae and impaired quality of survival • 3D intensity-modulated proton beam radiotherapy has potential advantages over photon beam methods to focus and limit the radiation effects to optic and hypothalamic structures • Preclinical, in vivo mouse models can be used to investigate the pathogenesis of adamantinomatous craniopharyngioma and to test novel treatments and thus whether therapies should either aim to inhibit or promote activity of a particular pathway. In our view, robust preclinical data are imperative before translating findings to the clinic, as some of the deregulated pathways might have functions that are tumour-context dependent, and thus their therapeutic value needs to be assessed specifically in each tumour. Nonetheless, as in any targeted therapy, drug resistance can arise, although the low mutational burden of adamantinomatous craniopharyngioma tumours might prevent the acquisition of such resistance.
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Preclinical models
Several attempts have been made to establish preclinical models of human adamantinomatous craniopharyngioma, ranging from primary cell cultures to genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs).
Primary cells from human adamantinomatous craniopharyngioma samples have been isolated and used for diverse studies to assess the effects of WNT-β-catenin, claudin 1 and epidermal growth factor (EGF) pathways in cell migration and invasion [28] [29] [30] . Although these experiments are encouraging and informative, molecular profiling of these tumour cells has not been carried out. In addition, these cells cannot be easily cultured and passaged. Further characterization of these cells (for example, the degree of molecular similarity to human tumours) and optimization of culture conditions are required to achieve the maximum potential of this in vitro cell model.
A GEMM has been generated by expressing a mutant (degradation-resistant) form of β-catenin in undifferentiated embryonic precursors of the pituitary gland (that is, the embryonic adamantinomatous craniopharyngioma mouse model) 23 . Interestingly, when oncogenic β-catenin is expressed in committed progenitors (for example, pituitary-specific positive transcription factor 1 (Pit1)-expressing cells) or hormone-producing cells (for example, somatotrophs), no tumours develop, which suggests that only undifferentiated progenitors provide the cellular context that is required for tumours to form. As this oncogenic β-catenin is functionally equivalent to that identified in human adamantinomatous craniopharyngioma, the molecular aetiology of this GEMM is similar to that of the human tumour.
Several histological and molecular features are conserved between mouse and human tumours. As it has been observed in humans, mouse tumours show cystic and solid components, are synaptophysin negative and do not express hormones 23 . The pituitary gland of these mice at birth and early postnatal stages shows the presence of cell clusters with nucleocytoplasmic accumulation of β-catenin 23 , which is typical of human adamantinomatous craniopharyngioma. However, murine tumours do not show a palisading epithelium, wet keratin or any sign of calcification, all of which are common features of the human tumours. Similarly, mouse tumours do not infiltrate the brain or visual pathways, whereas this infiltration is a common finding in humans 22 . Despite the histological differences, molecular analyses of mouse tumours have predicted the upregulation of several pathways in the human tumour, which have been subsequently confirmed in human studies (for example, sonic hedgehog (SHH) and C-X-C chemokine receptor type 4 (CXCR4)) [31] [32] [33] . This model, therefore, has similar molecular aetiology and pathogenesis compared to human adamantinomatous craniopharyngioma, although species-specific differences exist that need to be considered 34 . A second GEMM has been obtained by targeted expression of oncogenic β-catenin in adult SOX2-expressing (SOX2 + ) pituitary stem cells (that is, the inducible mouse adamantinomatous craniopharyngioma model) 35 . The resulting tumours also show a degree of resemblance to human adamantinomatous craniopharyngioma; specifically, these murine tumours are nonsecreting and have β-catenin-accumulating cell clusters. However, as in the embryonic model, the tumours lack A schematic representation of the major genes and deregulated pathways in adamantinomatous craniopharyngioma that result from activating mutations in β-catenin (which is encoded by CTNNB1) is shown. Most, if not all, adamantinomatous craniopharyngioma tumours harbour mutations in CTNNB1, which directly result in overactivation of the WNT-β-catenin pathway. Overactivation of this pathway is evidenced by the expression of target genes such as AXIN2 and lymphoid enhancer-binding factor 1 (LEF1). As a result of this initial oncogenic hit (defined as the driver mutation), several further genes and pathways become deregulated, which probably affect multiple biological processes such as cell proliferation, survival, differentiation, inflammation, angiogenesis, adhesion and tumour infiltration, among others. The colour code indicates the potential involvement of the deregulated pathways in these biological processes, as deduced from other cellular and/or tumoural contexts. This assessment is not exclusive, as many pathways might be involved either directly or indirectly in several, or all, processes that are indicated. Knowing whether inhibition or stimulation of some of these pathways might be of therapeutic use requires robust preclinical data to confirm their pathogenic effects. AREG, amphiregulin; BMP, bone morphogenetic protein; CXCL12, C-X-C motif chemokine ligand 12; CXCR4, C-X-C chemokine receptor type 4; EGF, epidermal growth factor; EGFR, EGF receptor; FGF, fibroblast growth factor; IL-2Rβ, interleukin-2 receptor, beta chain; MMP9, matrix metalloproteinase 9; PTCH1, protein patched homologue 1; PTGS2, prostaglandinendoperoxide synthase 2; SHH, sonic hedgehog.
some common histological features of the human tumours (for example, palisading epithelium and wet keratin) and do not infiltrate the brain or visual pathways. Importantly, these GEMMs have revealed that paracrine activity of mutated progenitors and/or stem cells might be crucial in controlling the growth and behaviour of adamantinomatous craniopharyngioma, a concept that could have additional implications in the cancer field 36 . Specifically, SOX2
+ pituitary stem cells have been targeted to express oncogenic β-catenin simultaneously with a fluorescent reporter that allows genetic tracing of the descendants of targeted SOX2 + cells 35 . These experiments have revealed that the murine tumours are not derived from the targeted SOX2 + cells; instead, these mutant SOX2 + cells proliferate transiently while accumulating β-catenin, then stop dividing but persist, generating the β-catenin-accumulating cell clusters. As the mutated cells stop proliferating, asking how the tumours form is an important question. Molecular profiling of the murine clusters has revealed the expression of a plethora of signalling molecules, which include proliferative and survival signals, as well as inflammatory cytokines and chemokines, which are hypothesized to generate a pro-tumorigenic microenvironment that results in the transformation of neighbouring cells 31 
(FIG. 2).
This paracrine model has been shown to be relevant to other murine neoplasias such as hepatocellular carcinoma and leukaemia 36, 37 . PDXs have also been developed by transplanting biopsy samples from human adamantinomatous craniopharyngioma either subcutaneously 38, 39 or intra cranially 40 into immunosuppressed mice. In these models, the cellular architecture of the original tumour is maintained, and thus these models are suitable to test the effects of potential therapies and to further understand the biology of these neoplasias. Using the intracranial model, the paracrine activities of the clusters have been proposed to be crucial in controlling the infiltrative behaviour of human adamantinomatous craniopharyngioma 40 , a finding that is compatible with the reported 3D structure of these tumours 41 . PDXs are certainly very promising tools but have also some limitations. For instance, the tumours develop in an immunosuppressed environment, but inflammation probably has a crucial role in the pathogenesis of these neoplasias 27, 31, 42, 43 . In addition, the rareness of human adamantinomatous craniopharyngioma makes it challenging to obtain biopsy samples, and the slow growth of the engrafted tumours might make any analysis difficult (TABLE 1) .
In conclusion, several preclinical models of human adamantinomatous craniopharyngioma exist, each of which has advantages and disadvantages. We anticipate that the combined use of some of, or all, these models might be required to assess the pathogenicity of particular pathways and the potential therapeutic efficacy of selective drugs.
Surgery
The surgical management of craniopharyngioma in children remains one of the most controversial topics in paediatric neurosurgery. Theoretically, the benign histology implies that total surgical excision should be sufficient to provide a cure.
In the past, large paediatric surgical series have shown surgical success by radically resecting craniopharyngiomas [44] [45] [46] [47] [48] [49] . However, the associated mortality (up to 50% at 10 years after resection) and the high rate of recurrence despite surgical clearance (up to 50% in some series) became apparent, and it has been widely established that, in certain cases, total excision can lead to unacceptable hypothalamic injury [50] [51] [52] [53] . Currently, the state-of-the-art surgical management of craniopharyngioma is now turning to multimodal treatment strategies (combining surgery and radiotherapy) aimed to limit morbidity. In the early 2000s, a treatment strategy was proposed by the neuro surgical team at Necker-Enfants Malades Hospital in Paris, France, that could be adapted according to the degree of hypothalamic involvement as shown by preoperative MRI 53, 54 . Subsequent technical advances such as neuronavigation, endoscopy (combined with microscopic resection for transcranial approaches or solely for endonasal trans-sphenoidal approaches) and per-operative imaging might help the neurosurgeon to safely remove the craniopharyngioma and preserve hypothalamic structures [53] [54] [55] . 
Primary management
In emergency
In some patients with signs of raised intracranial pressure and/or vision loss, urgent surgical decompression is required. In those cases, the clinical signs are mainly linked to hydrocephalus due to a craniopharyngioma cyst that has developed in the third ventricle and that impairs the cerebrospinal fluid pathways. A ventriculoperitoneal shunt should be avoided (owing to a risk of dysfunction and to the fact that hyperdrainage can prevent a further safe transcallosal approach), and decompression of the cyst is recommended by placement of a catheter and eventually an Ommaya reservoir to allow repeated aspiration. The catheter can be placed during an open surgery (rare), a stereotactic procedure of preferably an endoscopic approach. Importantly, the decompression of a cyst might help to refine the risk grade 55 .
Cystic craniopharyngioma
Intracystic therapies can be implemented after a permeability test that is performed 1-2 weeks after the initial surgery (injection of contrast medium into the subcutaneous reservoir). Chemotherapy (bleomycin) or radiotherapy agents ( 90 Y and 32 P) had some success but have been associated with neurotoxicity or even death and have not proved to be consistently efficacious 56 . The most effective intracystic treatment with the best benefitto-risk ratio seems to be INFα. However, as with other intracystic therapies, the effect is limited to the cystic portion, with no effect on the solid component, and no published data are available yet on progression-free survival after this treatment 56, 57 .
Hypothalamic involvement
The neurosurgeon will plan surgery on the basis of two criteria. First, aiming at a total resection, surgery is planned according to hypothalamic involvement (risk grading 0, 1 or 2). Second, the best surgical route is chosen according to the location of the tumour and the identification of some anatomical hallmarks. Anatomical hallmarks important to identify before surgery include the length of the optic nerve pathways, the location of the anterior communicant artery, the sellar diaphragm, the hypothalamic structures (mammillary bodies and the shape of the third-ventricle floor), the size of the ventricles and the presence of a septum pellucidum.
In grade 0, there is no hypothalamic involvement, and most of these tumours develop in the sellar region under the sellar diaphragm. An endoscopic endonasal trans-sphenoidal route is ideal in these cases but has not been commonly used in paediatric patients with craniopharyngioma owing to their rarity relative to adult patients with craniopharyngioma and also to unfavourable anatomic conditions in children such as small nostrils, non-pneumatized sphenoid sinus or short intercarotid distance 58 . However, in experienced teams, young patients' age does not seem to be an obstacle, and an increasing number of publications report the success of this technique [59] [60] [61] . Although some reports have claimed to avoid hypothalamic dysfunction with the endoscopic endonasal trans-sphenoidal approach 62, 63 , it must be emphasized that most tumours approached via this route are infra-diaphragmatic in location 64 .
In grade 1, the craniopharyngioma is in contact with the hypothalamus, which is pushed or compressed (as identified by preoperative MRI). In some cases, according to the skills of the neurosurgeon and the extension of the craniopharyngioma, an endoscopic endonasal trans-sphenoidal approach can be performed, although a transcranial route has been traditionally used.
In grade 2, the hypothalamus is invaded by the craniopharyngioma and cannot be easily identified. Transcallosal, pterional and unilateral or bilateral subfrontal approaches represent the most frequent transcranial routes. Different approaches can be performed in the same patient, in whom staged surgeries are planned to preserve hypothalamic structures. In case of lower displacement of hypothalamic structures, a transcallosal or lamina terminalis approach is the preferred option. By contrast, an upper displacement of these structures should lead to a pterional or subfrontal approach. As the goal in this group of craniopharyngiomas is to preserve the invaded hypothalamus, the endoscopic endonasal trans-sphenoidal route is not recommended in these children, as using this endoscopic approach to anticipate the location of the remaining hypothalamus and perforating arteries is difficult.
In fact, many craniopharyngiomas originate primarily in the infundibulum and/or tuber cinereum, and expand within the hypothalamus itself. These craniopharyngiomas represent the subpopulation that is associated with the highest adherence, highest rate of recurrence and worst outcome 65 . Several reports support the need for a hypothalamus-referenced classification of craniopharyngiomas [66] [67] [68] [69] . About 40% of craniopharyngiomas in the different series present with a predominant involvement of the hypothalamus 70, 71 . Surgical treatment of rare paediatric craniopharyngioma lesions is very challenging and thus should be performed in experienced centres. In cases of grade 2 hypothalamic involvement, we recommend decreasing the size of the tumour as much as possible before irradiation, by combined surgeries if necessary. For children, and especially the youngest, with isolated endocrine deficits but without visual impairment or signs of raised intracranial pressure, a close follow-up using MRI should be discussed to gain time and postpone irradiation (in the case of hypothalamus involvement).
Radiation therapy
Radiation therapy is an effective means to achieve longterm disease control in children who are diagnosed with craniopharyngioma. Advanced methods in radiation therapy, including highly focused methods of intensitymodulated photon and proton therapy, have been used with more-generalized target volume-reduction strategies to improve the therapeutic ratio and increase the margin of safety 72 . Understanding that these patients present with significant comorbidities and are subject to sometimes unavoidable effects of the tumour and of the surgery before irradiation helps to balance treatment recommendations and promote acceptance of irradiation as a primary treatment modality with proper attribution of long-term effects.
Craniopharyngioma can be irradiated after a neuroimaging diagnosis and without surgical intervention. Although these cases are not common, they comprise a unique group of patients who can be followed-up for radiation-related complications in the absence of contributions from other treatments. An increasing proportion of children are treated with transnasal or trans-sphenoidal surgery with goals that are similar to those of transcranial surgery (that is, to decompress the tumour and improve or avoid symptoms), including attempted gross total resection. The advantage of the transnasal approach has yet to be demonstrated in children who require irradiation; however, this less invasive approach will create a new cohort of children who can be evaluated for outcomes and both acute and late effects of treatment. Practical and early observations are concerns about the use of the transnasal approach in children with extensive and cystic tumours, in whom the non-resected tumour might be prone to pseudotumour and cystic expansion during irradiation and thus necessitates transcranial intervention. That diabetes insipidus is generally accepted to develop after transnasal surgery and might be avoided by the transcranial approach is another consideration. Teams that favour less invasive surgery (so-called limited surgery) and radiation therapy use surgery (resection or catheter placement) to alleviate symptoms, such as vision loss or other obvious neurological deficits, establish a diagnosis in the setting of an equivocal neuroimaging assessment and prevent symptoms when further progression might affect optic pathways, result in hydrocephalus, compress neurological tissues such as the brainstem and increase the risks that are associated with irradiation. Indeed, surgery can be used to decrease the risks that are associated with irradiation when resection reduces the targeted volume, increases the distance between target and crucial normal tissue structures, or reduces the mass effect, which might compromise tissues and increase the risk of severe complications such as necrosis and vasculopathy.
Target volumes for radiation therapy are best delineated by multiplanar, multisequence MRI. CT is required for calculating the dose of radiation and has a vital role in the treatment-planning process for the assurance that it provides when the calcified tumour is included in the targeted volume. The borders between tumour and normal tissue are usually evident when not interrupted by surgery, and include borders where invasion or attachment might be present or boundaries where invasion or attachment might be improbable.
In radiation oncology, the gross tumour volume is defined as the residual tumour. In paediatric neuroradiotherapy (including treatment of craniopharyngioma), the gross tumour volume is often defined as the gross residual tumour and/or the tumour bed. When surgery is performed and portions of the tumour are resected or the borders of the tumour are interrupted, the definition of the gross tumour volume relies on the postoperative imaging findings, on the conversation between the surgeon and radiation oncologist, and on the experience and judgment of the radiation oncologist in considering the advantages and disadvantages of limiting the extent of the targeted volume. Classic parallel-opposed portals defined on planar X-ray imaging were replaced by CT-based treatment planning more than 20 years ago. Although the earliest experience with conformal treatment planning irradiated relatively large margins of normal tissue surrounding the post operative tumour complex, the move towards image-based treatment planning substantially reduced the amount of normal brain that is collaterally irradiated and defined a new cohort of children for the evaluation of disease control and treatment-related complications. The distinction between the two eras is important, as late-effects researchers focus on complications and the attribution of late effects to radiation in future patients.
The clinical target volume margin -the anatomically defined margin surrounding the gross tumour volume -has changed considerably using photon therapy during the past two decades, ranging from 2 to 10 mm (REFS 73, 74) , and depends on specific immobilization, verification and delivery methods. The smallest target volume margins were used in highly selected patients on the basis of the physical limitations of treatment devices and were constrained to patients with small tumours (<6 mm in diameter). More-generalized conformal therapy methods, including intensity-modulated photon therapy, permitted treatment of larger tumours and the systematic study of target volume reduction. Understanding that the size and shape of the tumour might change during treatment in some patients has made craniopharyngioma a leading indication for on-line and off-line imaging during irradiation, including the use of MRI on a weekly basis or less often when imaging early in the treatment course demonstrates stability of the tumour complex. The lack of cooperative or multi-institutional clinical trials involving radiation therapy for craniopharyngioma has limited consensus on the appropriate target volume for irradiation; however, on the basis of published reports and current listed trials, the clinical target volume margin for craniopharyngioma ranges from 3 to 5 mm. Nature Reviews | Endocrinology Nature Reviews | Endocrinology CGE ≤10. 8 
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Most treating physicians target both the postoperative tumour bed and the residual tumour, perform imaging at several time points during the treatment course and use image guidance regardless of the modality (FIG. 3) . A third aspect of basic clinical target volume definition is now in development: the planning target volume. This margin surrounds the clinical target volume geometrically and is meant to account for variation in patient treatment set-up. Variability in patient set-up remains important for both photon and proton planning; however, the latter requires consideration of range uncertainty, which can vary on a beam-by-beam basis. As very few beams are used with proton therapy and proton beams are more susceptible to changes in the tissue path length, robust proton treatment plans should include variability in target location, as well as changes in tissue composition and range calculation estimates. When prescribing proton therapy, an asymmetry exists in the final margin (planning target volume) that surrounds the previously defined clinical target volume.
Adverse effects
The rationale for radiation therapy and its potential adverse effects should be thoroughly understood by patients, their parents and caregivers. Acute effects of radiation therapy are less concerning and, when problematic, are related to treatment-induced cyst expansion. Most concerning is the broad effect of radiation therapy on cognitive function and the less-common but potentially more-serious complications of vasculopathy and necrosis. The cognitive effects of radiation therapy are associated with patient age, sex and key demographics, as well as with tumour-and treatment-related factors 75 , which include the presence or absence of hydrocephalus that requires treatment, the extent of disease and resection, and radiation dose and volume. Similar to that observed after treatment of other brain tumours, the adverse effect of radiation therapy is greater in children younger than 7-8 years of age and greatest in very young patients. Although no limit exists concerning the age at which irradiation can be administered in children with craniopharyngioma, the feasibility of surgery and other measures to delay or avoid irradiation should be considered for vulnerable patients. For those individuals at increased risk of late effects, the most advanced forms of radiation therapy should be considered, including pencil beam scanning proton therapy.
Craniopharyngioma has become one of the most common tumours that are treated with proton therapy. Children with craniopharyngioma can be rigorously immobilized, a requirement for proton therapy, and the relatively central location of the tumour and the homogeneous tissue path from surface to target reduce some of the physical uncertainties that are related to proton range. These uncertainties must be accounted for in the planning and delivery process. However, the sensitivity of protons to changes in tissue path length can be a cause for concern in patients who rapidly gain or lose weight during treatment or when cystic components of the tumour dynamically change the size and shape of the target. Early adopters of proton therapy that used the passive scattering method of delivery noted a marked change in the volume of normal tissue that received the lowest doses and unclear (no change or even a slight increase) modification of the volume of normal tissue adjacent to the target that received the highest doses. Newer methods of proton therapy, which are known as pencil beam or discrete spot scanning, use a magnetically positioned beam that delivers spots of protons, and therefore dose, to successive layers of the tumour as planned by treatment planning software and delivered by the energy selection and control systems of the proton accelerator and associated hardware. The difference is a more robust but less conformal passive scattering method than a less robust and highly conformal pencil beam scanning method 76 that reduces dose both adjacent to and at a distance from the target. Additional uncertainties of proton therapy that are related to linear energy transfer and radiobiological effectiveness demand careful monitoring of both common and less-common complications, as well as a comparison with highly annotated photon clinical data sets. Emerging data suggest the equivalence of proton therapy and photon therapy with regard to vasculopathy, necrosis and general neuro logical sequelae 77 . Investigators anticipate results supporting the hypothesis that cognitive outcomes are associated with radiation dose and volume and that the reduction in combinations of radiation dose and volume that is achieved through the use of proton therapy will preserve cognition in vulnerable patients.
In conclusion, craniopharyngioma has been a leading indication for proton therapy in children 78 . Proton therapy seems to be able to spare normal tissues from Long-term sequelae and prognosis Cardiovascular mortality is 3-19-fold higher in patients with craniopharyngioma than in the general population 7 . 20-year overall survival is impaired in patients who have craniopharyngioma with hypothalamic involvement 81, 82 . Hypothalamic obesity has a marked negative effect on long-term quality of survival 81 . Increased daytime sleepiness, fatigue, disturbances of circadian rhythms [83] [84] [85] [86] and eating behaviour [87] [88] [89] , gastrointestinal and pulmonary complaints (for example, diarrhoea and dyspnoea) 81 , memory deficits 90, 91 , endocrine and neuroendocrine deficiencies 92 , non-alcoholic fatty liver disease 93 and neuropsychological imbalances [94] [95] [96] [97] [98] [99] [100] are major long-term adverse effects in patients with craniopharyngioma and hypothalamic obesity. In 2015, hypothalamic involvement was reported to have a statistically significant negative effect on 20-year overall survival 81 . The degree of surgical resection had no effect on 20-year progressionfree survival in craniopharyngioma, which supports the concept that gross total resection is of no advantage in terms of tumour recurrence (FIG. 4) .
Treatment of hypothalamic obesity
Owing to disturbances in energy expenditure, central sympathetic output and appetite regulation, patients with craniopharyngioma and hypothalamic obesity typically develop morbid obesity that is mainly unresponsive to conventional lifestyle modification 1, [101] [102] [103] . Novel pharmaceutical treatment options for patients with craniopharyngioma and hypothalamic obesity have produced mixed results. On the basis of impairment of sympatho-adrenal activation and adrenaline production that manifests as a reduced hormonal response to hypoglycaemia, treatment of this disorder with amphetamine derivatives has been suggested 104 . Treatment of eight adult patients with hypothalamic obesity (six of whom had craniopharyngioma) with glucagon-like peptide 1 (GLP1) analogues resulted in substantial and sustained weight loss that was associated with improvements in metabolic and cardiovascular risk profiles 105 . Patients with craniopharyngioma have been reported to produce and secrete the hormone oxytocin, even when pituitary and hypothalamic structures are damaged 106 . However, patients with grade 1 hypothalamic damage, which involves damage only to the anterior hypothalamic areas, presented with a lower fasting level of oxytocin than patients with either grade 0 or grade 2 hypo thalamic damage. In addition, changes in oxytocin levels before and after standardized breakfast correlated with BMI, which demonstrates that patients with craniopharyngioma and hypothalamic obesity exhibit less variation in oxytocin secretion due to nutrition. Accordingly, the investigators speculated that oxytocin supplementation might be a therapeutic option in patients with craniopharyngioma and hypothalamic obesity and/or neurobehavioural deficits due to specific hypothalamic damage in the anterior hypothalamic area.
Initial experiences with bariatric surgery in patients with craniopharyngioma and severe obesity achieved sufficient tolerability and short-term weight reduction [107] [108] [109] . An instant improvement in binge-eating behaviour was observed in patients immediately after laparoscopic adjustable gastric banding, but long-term weight reduction was not achieved. Treatment with invasive, nonreversible bariatric methods such as Roux-en-Y gastric bypass is more efficient in achieving weight reduction 107 but controversial in the paediatric population owing to medical, ethical and legal considerations 109 . Despite the availability of promising therapeutic approaches 27 , it must be emphasized that currently no generally accepted therapy for hypothalamic obesity in patients with craniopharyngioma has been shown to be effective in randomized studies.
Risk-adapted treatment strategies
Risk-adapted treatment strategies 53, 55, 96, [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] focus on the following main goals: reversal of visual compression symptoms; relief of raised intracranial pressure; prevention of tumour regrowth and/or progression; and restoration or substitution of pituitary hormone deficits plus all other supplement-supportive measures while minimizing acute and long-term mortality and morbidity 1, 102, 120 (TABLE 3) .
The association between attempts at radical gross total resection in cases of hypothalamic involvement and long-term morbidity was first reported in 1996 (REF. 121 ). An algorithm for the surgical treatment of patients with craniopharnygioma 53, 111 , which recommends a hypothalamus-sparing strategy that is based on a grading of hypothalamic tumour involvement in preoperative MRI 53 , has been published. The same investigators reported that patients who were neurosurgically treated according to this algorithm using a hypothalamus-sparing approach had lower prevalence of severe obesity and similar relapse rates compared to patients treated by gross total resection (28% and 54%, respectively) 111 . This report was the first evidence proving the tolerability and efficacy of a hypothalamus-sparing strategy by comparing cohorts treated by the same experienced surgical team at a single institution and thus eliminating the bias of surgical experience on outcome analysis. However, although the hypothalamus-sparing surgery increased the percentage of 'normal' BMI from 17% to 38%, importantly, the likelihood of clinically significant weight gain remained 62%, with nearly half of the patients developing morbid obesity. A risk-adapted treatment strategy based on presurgical and postsurgical grading of hypothalamic involvement and/or damage in MRI has been reported 112, 113 . The assessment of the suprasellar tumour extension towards the mammillary bodies is considered essential for their grading of anterior or posterior hypothalamic involvement and/or lesion. According to these reports, patients with postsurgical lesions that affect posterior hypothalamic structures present with increased BMI and reduced self-assessed quality of life during long-term prospective follow-up (FIG. 5) . A treatment algorithm suggesting a two-staged surgical approach with initial relief of cystic pressure and thus down-staging the risk grade in appropriate cases has been proposed 55 .
As most patients in the aforementioned studies came from low-volume or low-experience centres, the long-term outcome data might be more applicable to 'community practice' than to high-volume surgical centres. Although one of the studies 111 was conducted in a large-volume centre 111 , it was still a single-institution, sequential study and not a multi-institutional, randomized or even case-control study. All the above-mentioned treatment strategies and algorithms recommend that, for craniopharyngioma with hypothalamic involvement, limited surgical approaches and postoperative external irradiation are advisable and that treatment of craniopharyngioma should be confined to experienced multidisciplinary teams.
A major step towards potential standardization of preoperative staging in craniopharyngioma is the comparison of published grading systems for the assessment of hypothalamic damage and/or involvement with regard to prediction value for severe hypothalamic obesity as the main sequela impairing the quality of survival. The sensitivity of three published grading systems [111] [112] [113] [114] for prediction of hypothalamic obesity in a single-centre cohort has been analysed 118 . Variables identified as factors with high and comparable prediction value for postoperative hypothalamic syndrome included the degree of hypothalamic involvement according to described classifications [111] [112] [113] [114] . These results support the hypothesis that disease-or treatment-related hypothalamic alterations have relevant negative effects on the quality of survival and prognosis in craniopharyngioma 2, 122 . A few studies analysing the prognosis of patients with craniopharyngioma in relation to neurosurgeons' experience have been reported 53, 112, 113, [123] [124] [125] [126] . Clinically significant differences in outcome according to the neuro surgeons' experience with the disease have also been reported 123, 124 . Degree of obesity and quality of life have also been analysed on the basis of reference assessment of tumour location and postsurgical hypothalamic lesions 113 . Treatment has also been analysed regarding neurosurgical strategy and neurosurgical centre size, which was based on patient load. Surgical lesions of anterior and posterior hypothalamic areas were associated with postsurgical obesity, negatively affecting long-term quality of survival in patients with surgical posterior hypothalamic lesions 112, 113 . Treatment strategies in large centres were less radical, and the rates of complete resection and hypothalamic surgical lesions were lower than those of middle and small-sized centres 112, 113, 126 .
However, in multivariate analysis, preoperative hypothalamic involvement was the only independent risk factor for severe obesity 113 . For favourably localized craniopharyngiomas, the preferred treatment of choice, especially at initial diagnosis, is to attempt complete resection with preservation of hypothalamic and visual function 1, 102, 111, 125, [127] [128] [129] [130] . For unfavourably localized tumours -those too close to or too entangled with the hypothalamus and/or the optic chiasm -a limited resection followed by irradiation should be considered to preserve integrity of, and/or to avoid further damage to, optic and hypothalamic structures 126, [131] [132] [133] [134] [135] [136] [137] [138] . Overall, surgical results reported by the most experienced and skilled surgeons after gross total removal of craniopharyngiomas (children and adult individuals combined) coincide with extremely low mortality (0-5%) and low morbidity due to hypothalamic damage (~10-15% on average). This finding is in apparent contradiction with the extreme heterogeneity regarding the pathological and clinical expression of these lesions and the common consideration of craniopharyngiomas as one of the most challenging lesions for the neuro surgeon, as reported in lectures and in personal communications. Neurosurgeons communicate dreadful experiences with individual cases of craniopharyngioma, but these are never reported in official journals. Surgical results should improve with the learning curve effect 47 , but this effect seems to be negligible judging by recent publications 53, 96, 111, 112 . The honesty displayed by the neurosurgical team at Necker-Enfante Malades Hospital in changing their craniopharyngioma treatment paradigm to limit the surgical risks that are associated with hypothalamic injury must be appreciated 111 . However, craniopharyngiomas represent a multifaceted, complex type of lesion, the treatment of which should never be planned under the 'rules' of a fixed protocol, irrespective of how experienced and/or skilled the team, surgeon or radiotherapist might be. In this sense, approaching craniopharyngiomas as a 'disease' or 'common pathological entity' is misleading, as comparisons between series including lesions with different topographies, sizes, shapes, consistencies, histologies and clinical impairments will neither yield sound results nor produce the desired outcome for an individual patient. No proper characterization of the subset of adamantinomatous cranio pharyngiomas in the child population versus the adult population has been provided to date. However, given the rarity of these lesions, it is the personal cautiousness and time invested in gaining maximal knowledge about every individual case, more than any dogmatic criteria established by professional and/or political authorities, that will make a difference to each patient.
Conclusions
In conclusion, the molecular pathogenesis of human adamantinomatous craniopharyngioma has started to be unveiled and offers the possibility of testing novel treatments targeting pathogenic pathways. Several preclinical models are available, and, although not perfect, they are suitable tools to investigate the role of these pathways in tumour biology and to determine their therapeutic potential against human adamantinomatous craniopharyngioma.
Proton therapy clearly reduces the collateral radiation dose to normal tissue compared with photon (X-ray)-based methods of irradiation. Preliminary results from first generation trials using proton therapy are anticipated.
Hopefully, published grading systems will support efforts in establishing standards for staging in craniopharyngioma, which should be implemented by national and international societies. Gross total resection should be avoided in craniopharyngiomas with hypothalamic involvement to prevent further hypothalamic damage. As surgical expertise has been shown to have an effect on postoperative morbidity, medical societies should establish criteria of adequate professional expertise for the treatment of craniopharyngioma. On the basis of these criteria, health authorities should organize the certification of centres of excellence that are authorized to treat and care for patients with this chronic disease.
